

Curriculum Vitae

Assoc. Prof. Gabriel Kamensky

Cardiologist, MD, PhD, FESC

Vth Internal Clinic, Dept. Non-invasive Cardiovascular Diagnostics, University Hospital Bratislava, Bratislava, Slovakia



National CVD Prevention Coordinator
for Slovakia

Contact: [email](#)

Short CV

- Medical Study at the Comenius University Medical School in Bratislava (1973- 1979)
- Board certification in Internal Medicine, Bratislava, 1983
- Board certification in cardiology, Bratislava, 1987
- PhD – Comenius University Medical School, Bratislava, 1987
- Associate Professor – Comenius University Medical School, Bratislava, 2003
- FESC – Fellow of the European Society of Cardiology, September 2004

Gabriel Kamensky is non-invasive and general cardiologist.

Main research fields: echocardiography, secondary prevention, hypertension, atrial fibrillation, heart failure.

He has published more than 240 scientific papers. He is member of the board and reviewer of a number of journals including:

- Cor et Vasa
- Cardiology Letters
- ECHOCARDIOGRAPHY: A Journal of Cardiovascular Ultrasound & Allied Techniques"
- POLSKI PRZEGLAD KARDIOLOGICZNY

Awards (sample):

- The Honorary member of the Slovak Society of Cardiology
- The Honorary member of the Czech Society of Cardiology
- Silver and gold medal of the Slovak Medical Society

Positions in societies and activities related to professional qualifications:

- the President of the Slovak Society of Cardiology (2003-2006);
- the chairman of the Working Group of Non-invasive Cardiology of the Slovak Society of Cardiology (1998-2003)
- Principal consultant for cardiology, the Slovak Ministry of Health Care (since 2005)
- The governor of the Slovak Heart Foundation (since 2006)
- The principal coordinator of the National Prevention CV Programme (2010-2012)

Addendum to Assoc. Prof. Kamensky's Curriculum Vitae

Selected publications

1. Studencan M; Kovar F; Hricak V; Kurray P; Goncalvesova E; Simkova I; **Kamensky G.** Two years survival of STEMI patients in Slovakia. An analysis of the SLOVak registry of Acute Coronary Syndromes (SLOVAKS). *Cor et Vasa*, Volume(s) 56, 24-Jul-2014, Pages e297-e303
2. Oldgren, J., Alings, M., Darius, H., Diener, H.-C., Eikelboom, J., Ezekowitz, M.D., **Kamensky, G.**, Reilly, P.A., Yang, S., Yusuf, S., Wallentin, L., Connolly, S.J. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: A subgroup analysis of the Re-Ly trial (2011) *Annals of Internal Medicine*, 155 (10), pp. 660-667.
3. Studenčan, M., Hricák, V., Kovář, F., Kurray, P., Murín, J., **Kamenský, G.**, Goncalvesová, E., Liška, B., Rosenberger, J., Baráková, A., Hlava, P. Implementation of ESC-STEMI guidelines into clinical practice: An analysis of the Slovak Registry of Acute Coronary Syndromes (SLOVAKS) (2011) *Journal of Cardiovascular Medicine*, 12 (5), pp. 353-355.
4. Nagarakanti, R., Ezekowitz, M.D., Oldgren, J., Yang, S., Chernick, M., Aikens, T.H., Flaker, G., Brugada, J., **Kamenský, G.**, Parekh, A., Reilly, P.A., Yusuf, S., Connolly, S.J. Dabigatran versus warfarin in patients with atrial fibrillation: An analysis of patients undergoing cardioversion (2011) *Circulation*, 123 (2), pp. 131-136.
5. McMurray, JV, Dunselman, P, Wedel, H, Cleland, JGF, Lindberg, M, Hjalmarson, Å, Kjekshus, J, Waagstein, F, Apetrei, E, Barrios, V, Böhm, M, **Kamensky, G**, Komajda, M, Mareev, V, Wikstrand J, on behalf of the CORONA Study Group. Coenzyme Q10, Rosuvastatin, and Clinical Outcomes in Heart Failure: A Pre-Specified Substudy of CORONA (Controlled Rosuvastatin Multinational Study in Heart Failure). *J. Am. Coll. Cardiol.* 2010;56;1196-1204
6. Mills, P., Timmis, A., Huber, K., Ector, H., Lancellotti, P., Masic, I., Ivanusa, M., Antoniades, L., Aschermann, M., Laucevicius, A., Mustonen, P., Artigou, J.-Y., Vardas, P., Stefanadis, C., Chiarello, M., Bolognese, L., Ambrosio, G., Van Der Wall, E.E., Kułakowski, P., Pinto, F.J., Apetrei, E., Oganov, R.G., **Kamensky, G.**, Lüscher, T.F., Lerch, R., Haouala, H., Sansoy, V., Shumakov, V., Tajer, C.D., Lau, C.-P., Márquez, M., Krittayaphong, R., Arai, K., Alfonso, F. The role of European national journals in education. (2009) *Heart*, 95 (24)
7. Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P.A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., Lewis, B.S., Darius, H., Diener, H.-C., Joyner, C.D., Wallentin, L., Alings, A.M.W., Amerena, J.V., Avezum, A., Baumgartner, I., Brugada, J., Budaj, A., Caicedo, V., Ceremuzynski, L., Chen, J.H., Commerford, P.J., Connolly, S.J., Dans, A.L., Darius, H., Di Pasquale, G., Diaz, R., Erol, C., Ezekowitz, M.D., Ferreira, J., Flaker, G.C., Flather, M.D., Franzosi, M.G., Gamboa, R., Golitsyn, S.P., Gonzalez Heramosillo, J.A., Halon, D., Heidbuchel, H., Hohnloser, S.H., Hori, M., Huber, K., Jansky, P., **Kamensky, G.**, Keltai, M., Kim, S., Lau, C.P., Le Heuzey, J.Y.F., Lewis, B.S., Liu, L.S., Nanas, J., Oldgren, J., Pais, P.S., Parkhomenko, A.N., Pedersen, K.E., Piegas, L.S., Raev, D., Razali, O.,

Simmers, T.A., Smith, P.J., Talajic, M., Tan, R.S., Tanomsup, S., Toivonen, L., Vinereanu, D., Wallentin, L., Xavier, D., Yusuf, S., Zhu, J. Dabigatran versus warfarin in patients with atrial fibrillation (2009) *New England Journal of Medicine*, 361 (12), pp. 1139-1151

8. Kamensky, G., Murin, J. Should cardiovascular disease prevention be undertaken by national cardiac societies? (2009) *Dialogues in Cardiovascular Medicine*, 14 (2), pp. 106-111.

9. McMurray JM, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, **Kamensky G**, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J for the CORONA Study Group. Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) A Retrospective Analysis. *Circulation* 2009;120:2188-2196.

10. Kamenský, G., Skoupá, J., Černá, V., Paluch, A., Grešová, I. Costs and benefits of preventive medical intervention in patients in Slovakia with high cardiovascular risk and within the age group of 45-64 years [Náklady a prínosy preventívnej medicamentóznej intervencie u pacientov s vysokým kardiovaskulárnym rizikom vo veku 45 až 64 rokov na Slovensku] (2008) *Kardiologia*, 17 (2), pp. 67-74.